1. Home
  2. FCF vs IMNM Comparison

FCF vs IMNM Comparison

Compare FCF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Commonwealth Financial Corporation

FCF

First Commonwealth Financial Corporation

SELL

Current Price

$20.29

Market Cap

2.2B

Sector

Finance

ML Signal

SELL

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$16.49

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCF
IMNM
Founded
1934
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.5B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
FCF
IMNM
Price
$20.29
$16.49
Analyst Decision
Buy
Strong Buy
Analyst Count
7
17
Target Price
$24.07
★ $35.19
AVG Volume (30 Days)
1.0M
★ 1.5M
Earning Date
10-27-2026
11-05-2026
Dividend Yield
★ 2.77%
N/A
EPS Growth
5.76
★ 51.40
EPS
★ 0.81
N/A
Revenue
N/A
★ $6,941,000.00
Revenue This Year
$6.49
N/A
Revenue Next Year
$5.68
$18,803.97
P/E Ratio
$24.95
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$15.00
$14.64
52 Week High
$22.34
$30.06

Technical Indicators

Market Signals
Indicator
FCF
IMNM
Relative Strength Index (RSI) 46.63 21.44
Support Level $19.85 N/A
Resistance Level $20.87 $23.48
Average True Range (ATR) 0.33 0.94
MACD 0.01 -0.29
Stochastic Oscillator 67.38 2.40

Price Performance

Historical Comparison
FCF
IMNM

About FCF First Commonwealth Financial Corporation

First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: